Alto Neuroscience (NYSE:ANRO) Price Target Raised to $25.00

Alto Neuroscience (NYSE:ANRO) had its target price lifted by Jefferies Financial Group from $15.00 to $25.00 in a research note published on Wednesday morning,Benzinga reports. Jefferies Financial Group currently has a buy rating on the stock.

Other analysts have also issued research reports about the company. Chardan Capital began coverage on Alto Neuroscience in a research report on Monday, September 29th. They issued a “buy” rating and a $15.00 target price on the stock. Robert W. Baird lifted their price objective on Alto Neuroscience from $10.00 to $16.00 and gave the company an “outperform” rating in a research note on Monday, October 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Alto Neuroscience in a research note on Wednesday, October 8th. Finally, HC Wainwright raised their target price on Alto Neuroscience from $10.00 to $50.00 and gave the company a “buy” rating in a report on Friday, October 24th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Alto Neuroscience currently has an average rating of “Moderate Buy” and an average price target of $23.20.

Alto Neuroscience Trading Up 5.8%

NYSE ANRO opened at $12.01 on Wednesday. The company has a debt-to-equity ratio of 0.20, a current ratio of 15.42 and a quick ratio of 18.43. The stock has a market capitalization of $373.21 million, a P/E ratio of -5.25 and a beta of 2.90. The firm’s 50-day moving average is $7.71 and its two-hundred day moving average is $4.51. Alto Neuroscience has a 12 month low of $1.60 and a 12 month high of $15.18.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.14. On average, sell-side analysts anticipate that Alto Neuroscience will post -2.54 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of Montreal Can acquired a new position in Alto Neuroscience during the 2nd quarter worth $25,000. Ground Swell Capital LLC acquired a new stake in Alto Neuroscience in the 2nd quarter valued at about $27,000. Vanguard Personalized Indexing Management LLC purchased a new position in shares of Alto Neuroscience in the 2nd quarter valued at about $33,000. AlphaCore Capital LLC boosted its stake in shares of Alto Neuroscience by 100.0% in the 2nd quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock valued at $44,000 after buying an additional 10,000 shares during the period. Finally, AQR Capital Management LLC acquired a new position in shares of Alto Neuroscience during the first quarter worth about $52,000.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.